Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001829126-25-008155
Filing Date
2025-10-15
Accepted
2025-10-15 20:28:41
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 22197
2 EXHIBIT 99.1 framework_ex99-1.htm EX-99.1 137482
3 EXHIBIT 99.2 framework_ex99-2.htm EX-99.2 6838
  Complete submission text file 0001829126-25-008155.txt   168209
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Subject) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-83670 | Film No.: 251396222
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 600 MONTGOMERY STREET, 42ND FLOOR SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET, 42ND FLOOR SAN FRANCISCO CA 94111 (628) 233-0357
Framework Ventures IV L.P. (Filed by) CIK: 0002028474 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D